http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Jul 2026 16:12:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747668.html si-local-file:///var/storage/secattach/20260708/26747668.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747668.html Wed, 08 Jul 2026 16:12:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747668.html si-local-file:///var/storage/secattach/20260708/26747668.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747668.html Wed, 08 Jul 2026 16:12:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747653.html si-local-file:///var/storage/secattach/20260708/26747653.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747653.html Wed, 08 Jul 2026 16:10:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747653.html si-local-file:///var/storage/secattach/20260708/26747653.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+07++Filed+by%3A+Bender+Jeremy/26747653.html Wed, 08 Jul 2026 16:10:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+03/26744218.html si-local-file:///var/storage/secattach/20260708/26744218.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+03/26744218.html Wed, 08 Jul 2026 07:18:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+03/26744218.html si-local-file:///var/storage/secattach/20260708/26744218.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jul+03/26744218.html Wed, 08 Jul 2026 07:18:00 -0400 AURA O.07116383 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732